foxo4-dri senolytic peptide human trial 2024 Targeting the FOXO4-p53 axis by retro-inverso agents: a pharmacological strategy to mitigate brain aging and cognitive decline | Naunyn-Schmiedeberg's Archives of Pharmacology Size:Box of 25x30 ml vials AOD 9604 (5MG) : Physical Product
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Sep 12 - Sep 17